FDA data reveal thousands of adverse event reports for Solensia, raising safety questions for the cat arthritis treatment.
Solensia, the first monoclonal antibody approved in the United States to control pain from osteoarthritis in cats, is drawing increased scrutiny as post-market safety data accumulates. Newly aggregated adverse event submissions to the Food and Drug Administration indicate thousands of reports since approval in early 2022. Veterinarians continue to use the monthly injection, but the growing dataset has sharpened attention on risk communication and follow-up monitoring.
The manufacturer, Zoetis, and regulators both emphasize that adverse event reports are signals rather than proof of causation. Even so, the breadth of real-world experiences is shaping how clinicians discuss benefits and risks with cat owners and how practices observe patients after each dose.
Why Solensia Was Welcomed In Clinics
Chronic osteoarthritis is common in older cats and can be difficult to manage because long-term use of many pain medicines is poorly tolerated. Solensia, known generically as frunevetmab, targets nerve growth factor – a protein involved in pain signaling – and is administered as a once-monthly injection. In pre-approval studies, cats receiving the antibody showed improved mobility and comfort compared with placebo, which helped drive early clinical enthusiasm.
For many practices, Solensia filled a therapeutic gap. Care teams appreciated a mechanism focused on pain modulation and an administration schedule that reduced the need for daily oral dosing. Owners reported practical benefits such as improved activity, easier grooming, and more reliable use of litter boxes, outcomes that matter in day-to-day quality of life.
What The FDA Reports Show
Post-approval, veterinarians and owners have submitted thousands of case reports to the FDA’s Center for Veterinary Medicine. The entries span a wide range of observations, from mild and transient signs to serious outcomes. Frequently listed issues include lethargy, vomiting, decreased appetite, and localized discomfort at the injection site. Some reports describe neurologic signs or kidney-related concerns, and a subset include deaths temporally associated with dosing.
Regulatory safety databases are designed to capture signals, not to establish cause and effect. Under-reporting, duplicate reporting, variable case detail, and the absence of untreated control groups all influence interpretation. Even so, large volumes of submissions prompt closer review, label refinements when warranted, and targeted communications to the veterinary community.
How Regulators And Zoetis Are Responding
As of the latest updates, the FDA has not announced a recall or imposed restrictions on Solensia. The agency continues routine pharmacovigilance, analyzes reporting trends, and encourages detailed submissions from clinics. Safety reviews often focus on patterns across time rather than individual cases, which helps identify potential risk factors such as concurrent disease, age, or prior medication history.
Zoetis states that the overall safety profile remains consistent with findings from clinical development and international experience with similar products. The company urges veterinarians to use the product according to labeling, assess each patient’s medical status, and report any suspected reactions to both Zoetis and regulators so that signals can be evaluated in context.
Balancing Benefits And Risks In Practice
For many cats, Solensia remains an important option when other therapies are limited or unsuitable. Clinicians often define success as a visible improvement in mobility and interaction at home, balanced against any adverse signs. Informed consent has become more detailed, with teams explaining common reactions, and outlining warning signs to watch.
